http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20010013025-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-335 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate | 1998-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20010013025-A |
| titleOfInvention | Method and compositions for administering taxanes orally to human patients |
| abstract | The present invention has been made so that the taxane antitumor agent, which has not been orally incompletely used in oral bioavailability, can be sufficiently used in vivo to orally administer to the human body showing the symptoms of taxane-reactive disease and obtain therapeutic blood levels. It is about. In a preferred embodiment, the taxanes (particularly paclitaxel) are co-administered to the patient with an oral cyclosporin enhancer, preferably cyclosporin A. In a preferred method of administration of the present invention, the first administration of the oral enhancer is administered within about 0.5-72 hours prior to the taxane administration, and the second administration is administered immediately before, immediately after or concurrently with the taxane administration. The present invention also relates to methods of providing treatments for patients exhibiting symptoms of taxane-reactive disease, as well as methods of providing such treatments and methods of preventing or alleviating hypersensitivity and allergic reactions without pre-administration. |
| priorityDate | 1997-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 306.